{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:47:26Z","timestamp":1782406046567,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K12 DA041449"],"award-info":[{"award-number":["K12 DA041449"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["NIH K23DA053433"],"award-info":[{"award-number":["NIH K23DA053433"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K23AR079035"],"award-info":[{"award-number":["K23AR079035"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Buprenorphine is the most commonly used medication for treating opioid use disorder (OUD). It may also be beneficial for individuals with chronic pain who are physically dependent on opioids but do not meet the criteria for OUD. Therefore, the buprenorphine patient population may be heterogeneous in terms of OUD and comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To characterize the heterogeneity of patient profiles among those initiating buprenorphine treatment in a large multi-state healthcare system, focusing on comorbid pain, psychiatric, and substance use disorder diagnoses, and other patient characteristics associated with profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study using electronic health record data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Partcipipants<\/jats:title>\n                    <jats:p>Patients with at least 12\u00a0months of data before a new buprenorphine prescription (OUD formulation) and at least 6\u00a0months of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Measures<\/jats:title>\n                    <jats:p>Presence vs absence of opioid use disorder diagnoses and latent class profiles of comorbid diagnoses and clinical characteristics. Post-index outcomes, including the number of buprenorphine orders and incidence of drug-related poisoning, were assessed for each class.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Results<\/jats:title>\n                    <jats:p>In a cohort of 5726 individuals (mean age 38.6\u00a0years, 56.2% female, 84.0% white), four latent classes were identified: (1) high multimorbidity burden; (2) moderate multimorbidity burden; (3) high rates of comorbid pain diagnoses but lower rates of psychiatric and substance use disorder diagnoses, with most patients lacking opioid use disorder diagnoses; (4) lower rates of pain diagnoses but high rates of comorbid psychiatric and substance use disorder diagnoses. Post-index measures aligned well with comorbidity profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients receiving buprenorphine in general healthcare settings likely form a heterogeneous group. This includes a subgroup with low rates of opioid use disorder diagnoses (class 2, pain comorbidity), who may resemble chronic pain patients more than conventional OUD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11606-026-10221-z","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:00:26Z","timestamp":1770048026000},"page":"2465-2473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Profiles of Buprenorphine Initiators in General Healthcare Settings: A Latent Class Approach"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8191-6875","authenticated-orcid":false,"given":"Richard A.","family":"Grucza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Y.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirti","family":"Veeramachaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Rottnek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey F.","family":"Scherrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"5","key":"10221_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.14328","volume":"6","author":"EA Taylor","year":"2023","unstructured":"Taylor EA, Cantor JH, Bradford AC, Simon K, Stein BD. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes. JAMA Netw Open. 2023;6(5):e2314328. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.14328","journal-title":"JAMA Netw Open."},{"key":"10221_CR2","doi-asserted-by":"publisher","first-page":"108130","DOI":"10.1016\/j.drugalcdep.2020.108130","volume":"213","author":"CM Mintz","year":"2020","unstructured":"Mintz CM, Presnall NJ, Sahrmann JM, et al. Age disparities in six-month treatment retention for opioid use disorder. Drug and Alcohol Dependence. 2020;213:108130-108130.","journal-title":"Drug and Alcohol Dependence."},{"issue":"4","key":"10221_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/ADM.0000000000000945","volume":"16","author":"SM Cohen","year":"2022","unstructured":"Cohen SM, Weimer MB, Levander XA, Peckham AM, Tetrault JM, Morford KL. Low Dose Initiation of Buprenorphine: A Narrative Review and Practical Approach. Journal of Addiction Medicine. 2022;16(4):399-406. https:\/\/doi.org\/10.1097\/ADM.0000000000000945","journal-title":"Journal of Addiction Medicine."},{"issue":"3","key":"10221_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.bpa.2020.06.005","volume":"34","author":"I Urits","year":"2020","unstructured":"Urits I, Pham C, Swanson D, et al. The utilization of buprenorphine in chronic pain. Best Practice & Research Clinical Anaesthesiology. 2020;34(3):355-368. https:\/\/doi.org\/10.1016\/j.bpa.2020.06.005","journal-title":"Best Practice & Research Clinical Anaesthesiology."},{"key":"10221_CR5","unstructured":"Kumar R, Viswanath O, Saadabadi A. Buprenorphine. In: StatPearls. StatPearls Publishing; 2023. Accessed September 7, 2023. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459126\/"},{"issue":"4","key":"10221_CR6","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/pm\/pny307","volume":"20","author":"K Kroenke","year":"2019","unstructured":"Kroenke K, Alford DP, Argoff C, et al. Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report. Pain Med. 2019;20(4):724-735. https:\/\/doi.org\/10.1093\/pm\/pny307","journal-title":"Pain Med."},{"issue":"2","key":"10221_CR7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/08897077.2017.1381663","volume":"39","author":"A Manhapra","year":"2018","unstructured":"Manhapra A, Arias AJ, Ballantyne JC. The Conundrum of Opioid Tapering in Long-Term Opioid Therapy for Chronic Pain: A Commentary. Substance Abuse. 2018;39(2):152-161. https:\/\/doi.org\/10.1080\/08897077.2017.1381663","journal-title":"Substance Abuse."},{"issue":"4","key":"10221_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/AJP.0b013e318298ddad","volume":"30","author":"K Rosen","year":"2014","unstructured":"Rosen K, Gutierrez A, Haller D, Potter JS. Sublingual Buprenorphine for Chronic Pain: A Survey of Clinician Prescribing Practices. The Clinical Journal of Pain. 2014;30(4):295-300. https:\/\/doi.org\/10.1097\/AJP.0b013e318298ddad","journal-title":"The Clinical Journal of Pain."},{"key":"10221_CR9","doi-asserted-by":"publisher","unstructured":"Sandbrink F, Murphy JL, Johansson M, et al. The Use of Opioids in the Management of Chronic Pain: Synopsis of the 2022 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Ann Intern Med. 2023;176(3):388\u2013397. https:\/\/doi.org\/10.7326\/M22-2917","DOI":"10.7326\/M22-2917"},{"issue":"Suppl 3","key":"10221_CR10","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1007\/s11606-020-06251-w","volume":"35","author":"A Manhapra","year":"2020","unstructured":"Manhapra A, Sullivan MD, Ballantyne JC, MacLean RR, Becker WC. Complex Persistent Opioid Dependence with Long-term Opioids: a Gray Area That Needs Definition, Better Understanding, Treatment Guidance, and Policy Changes. J Gen Intern Med. 2020;35(Suppl 3):964-971. https:\/\/doi.org\/10.1007\/s11606-020-06251-w","journal-title":"J Gen Intern Med."},{"issue":"6","key":"10221_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.7326\/M19-1488","volume":"171","author":"R Chou","year":"2019","unstructured":"Chou R, Ballantyne J, Lembke A. Rethinking Opioid Dose Tapering, Prescription Opioid Dependence, and Indications for Buprenorphine. Ann Intern Med. 2019;171(6):427. https:\/\/doi.org\/10.7326\/M19-1488","journal-title":"Ann Intern Med."},{"issue":"17","key":"10221_CR12","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/archinternmed.2012.3212","volume":"172","author":"JC Ballantyne","year":"2012","unstructured":"Ballantyne JC, Sullivan MD, Kolodny A. Opioid Dependence vs Addiction: A Distinction Without a Difference? Arch Intern Med. 2012;172(17):1342-1343. https:\/\/doi.org\/10.1001\/archinternmed.2012.3212","journal-title":"Arch Intern Med."},{"issue":"7","key":"10221_CR13","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s11864-022-00985-x","volume":"23","author":"A Manhapra","year":"2022","unstructured":"Manhapra A. Complex Persistent Opioid Dependence-an Opioid-induced Chronic Pain Syndrome. Curr Treat Options Oncol. 2022;23(7):921-935. https:\/\/doi.org\/10.1007\/s11864-022-00985-x","journal-title":"Curr Treat Options Oncol."},{"issue":"8","key":"10221_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.26523","volume":"5","author":"MR Larochelle","year":"2022","unstructured":"Larochelle MR, Lodi S, Yan S, Clothier BA, Goldsmith ES, Bohnert ASB. Comparative Effectiveness of Opioid Tapering or Abrupt Discontinuation vs No Dosage Change for Opioid Overdose or Suicide for Patients Receiving Stable Long-term Opioid Therapy. JAMA Netw Open. 2022;5(8):e2226523. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.26523","journal-title":"JAMA Netw Open."},{"issue":"4","key":"10221_CR15","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/ajad.13153","volume":"30","author":"ZEH Latif","year":"2021","unstructured":"Latif ZEH, Skjaerv\u00f8 I, Solli KK, Tanum L. Chronic Pain Among Patients With an Opioid Use Disorder. Am J Addict. 2021;30(4):366-375. https:\/\/doi.org\/10.1111\/ajad.13153","journal-title":"Am J Addict."},{"key":"10221_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jsat.2017.03.006","volume":"77","author":"YI Hser","year":"2017","unstructured":"Hser YI, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Huang D. Chronic pain among patients with opioid use disorder: Results from electronic health records data. J Subst Abuse Treat. 2017;77:26-30. https:\/\/doi.org\/10.1016\/j.jsat.2017.03.006","journal-title":"J Subst Abuse Treat."},{"issue":"2","key":"10221_CR17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s11606-006-0050-y","volume":"22","author":"DT Barry","year":"2007","unstructured":"Barry DT, Moore BA, Pantalon MV, et al. Patient satisfaction with primary care office-based buprenorphine\/naloxone treatment. J Gen Intern Med. 2007;22(2):242-245. https:\/\/doi.org\/10.1007\/s11606-006-0050-y","journal-title":"J Gen Intern Med."},{"issue":"23","key":"10221_CR18","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-World Evidence \u2014 What Is It and What Can It Tell Us? N Engl J Med. 2016;375(23):2293-2297. https:\/\/doi.org\/10.1056\/NEJMsb1609216","journal-title":"N Engl J Med."},{"issue":"5","key":"10221_CR19","doi-asserted-by":"publisher","first-page":"e2211363","DOI":"10.1001\/jamanetworkopen.2022.11363","volume":"5","author":"KY Xu","year":"2022","unstructured":"Xu KY, Mintz CM, Presnall N, Bierut LJ, Grucza RA. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use. JAMA Network Open. 2022;5(5):e2211363-e2211363.","journal-title":"JAMA Network Open."},{"issue":"3","key":"10221_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","volume":"71","author":"D Dowell","year":"2022","unstructured":"Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep. 2022;71(3):1-95. https:\/\/doi.org\/10.15585\/mmwr.rr7103a1","journal-title":"MMWR Recomm Rep."},{"issue":"3","key":"10221_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.0522","volume":"7","author":"L Yemane","year":"2024","unstructured":"Yemane L, Mateo CM, Desai AN. Race and Ethnicity Data in Electronic Health Records\u2014Striving for Clarity. JAMA Netw Open. 2024;7(3):e240522. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.0522","journal-title":"JAMA Netw Open."},{"issue":"1","key":"10221_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.mcna.2021.08.006","volume":"106","author":"LR Marks","year":"2022","unstructured":"Marks LR, Nolan NS, Liang SY, Durkin MJ, Weimer MB. Infectious Complications of Injection Drug Use. Med Clin North Am. 2022;106(1):187-200. https:\/\/doi.org\/10.1016\/j.mcna.2021.08.006","journal-title":"Med Clin North Am."},{"issue":"9","key":"10221_CR23","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jama.2012.234","volume":"307","author":"KH Seal","year":"2012","unstructured":"Seal KH, Shi Y, Cohen G, et al. Association of mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan. JAMA. 2012;307(9):940-947. https:\/\/doi.org\/10.1001\/jama.2012.234","journal-title":"JAMA."},{"key":"10221_CR24","doi-asserted-by":"crossref","unstructured":"Masyn KE. Latent class analysis and finite mixture modeling. In: The Oxford Handbook of Quantitative Methods: Statistical Analysis, Vol. 2. Oxford library of psychology. Oxford University Press; 2013:551\u2013611.","DOI":"10.1093\/oxfordhb\/9780199934898.013.0025"},{"key":"10221_CR25","doi-asserted-by":"crossref","unstructured":"McCutcheon AL. Latent Class Analysis. Vol 64. Sage; 1987.","DOI":"10.4135\/9781412984713"},{"issue":"4","key":"10221_CR26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/10705510701575396","volume":"14","author":"KL Nylund","year":"2007","unstructured":"Nylund KL, Asparouhov T, Muth\u00e9n BO. Deciding on the Number of Classes in Latent Class Analysis and Growth Mixture Modeling: A Monte Carlo Simulation Study. Structural Equation Modeling: A Multidisciplinary Journal. 2007;14(4):535-569. https:\/\/doi.org\/10.1080\/10705510701575396","journal-title":"Structural Equation Modeling: A Multidisciplinary Journal."},{"issue":"1","key":"10221_CR27","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1097\/CCM.0000000000004710","volume":"49","author":"P Sinha","year":"2021","unstructured":"Sinha P, Calfee CS, Delucchi KL. Practitioner\u2019s Guide to Latent Class Analysis: Methodological Considerations and Common Pitfalls. Crit Care Med. 2021;49(1):e63-e79. https:\/\/doi.org\/10.1097\/CCM.0000000000004710","journal-title":"Crit Care Med."},{"key":"10221_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.918371","volume":"13","author":"C Rauschert","year":"2022","unstructured":"Rauschert C, Seitz NN, Olderbak S, Pogarell O, Dreischulte T, Kraus L. Subtypes in Patients Taking Prescribed Opioid Analgesics and Their Characteristics: A Latent Class Analysis. Front Psychiatry. 2022;13:918371. https:\/\/doi.org\/10.3389\/fpsyt.2022.918371","journal-title":"Front Psychiatry."},{"issue":"7","key":"10221_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219717","volume":"14","author":"M Afshar","year":"2019","unstructured":"Afshar M, Joyce C, Dligach D, et al. Subtypes in patients with opioid misuse: A prognostic enrichment strategy using electronic health record data in hospitalized patients. PLoS One. 2019;14(7):e0219717. https:\/\/doi.org\/10.1371\/journal.pone.0219717","journal-title":"PLoS One."},{"issue":"8","key":"10221_CR30","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.jpain.2022.03.236","volume":"23","author":"S Rodr\u00edguez-Espinosa","year":"2022","unstructured":"Rodr\u00edguez-Espinosa S, Coloma-Carmona A, P\u00e9rez-Carbonell A, Rom\u00e1n-Quiles JF, Carballo JL. Differential Experience of Interdose Withdrawal During Long-Term Opioid Therapy and its Association With Patient and Treatment Characteristics: A Latent Class Analysis in Chronic Pain Population. J Pain. 2022;23(8):1427-1436. https:\/\/doi.org\/10.1016\/j.jpain.2022.03.236","journal-title":"J Pain."},{"issue":"3","key":"10221_CR31","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/j.1360-0443.2010.03217.x","volume":"106","author":"FL Shand","year":"2011","unstructured":"Shand FL, Slade T, Degenhardt L, Baillie A, Nelson EC. Opioid dependence latent structure: two classes with differing severity? Addiction. 2011;106(3):590-598. https:\/\/doi.org\/10.1111\/j.1360-0443.2010.03217.x","journal-title":"Addiction."},{"issue":"4","key":"10221_CR32","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/dar.13634","volume":"42","author":"L Archambault","year":"2023","unstructured":"Archambault L, Bertrand K, Jutras-Aswad D, Monson E, Tour\u00e9 EH, Perreault M. People with opioid use disorders: A taxonomy of treatment entrants to support the development of a profile-based approach to care. Drug Alcohol Rev. 2023;42(4):765-777. https:\/\/doi.org\/10.1111\/dar.13634","journal-title":"Drug Alcohol Rev."},{"issue":"Pt 2","key":"10221_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2021.106729","volume":"152","author":"MS Ellis","year":"2021","unstructured":"Ellis MS, Kasper ZA, Cicero TJ. Polysubstance use trends and variability among individuals with opioid use disorder in rural versus urban settings. Prev Med. 2021;152(Pt 2):106729. https:\/\/doi.org\/10.1016\/j.ypmed.2021.106729","journal-title":"Prev Med."},{"issue":"1","key":"10221_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13722-023-00405-x","volume":"18","author":"JF Scherrer","year":"2023","unstructured":"Scherrer JF, Sullivan MD, LaRochelle MR, Grucza R. Validating opioid use disorder diagnoses in administrative data: a commentary on existing evidence and future directions. Addiction Science & Clinical Practice. 2023;18(1):1-5.","journal-title":"Addiction Science & Clinical Practice."},{"issue":"9","key":"10221_CR35","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","volume":"76","author":"PA Lagisetty","year":"2019","unstructured":"Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine Treatment Divide by Race\/Ethnicity and Payment. JAMA Psychiatry. 2019;76(9):979-981. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.0876","journal-title":"JAMA Psychiatry."},{"issue":"2","key":"10221_CR36","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","volume":"76","author":"ND Volkow","year":"2019","unstructured":"Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and Treatment of Opioid Misuse and Addiction: A Review. JAMA Psychiatry. 2019;76(2):208-216. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.3126","journal-title":"JAMA Psychiatry."},{"issue":"4","key":"10221_CR37","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/pm\/pnz356","volume":"21","author":"L Webster","year":"2020","unstructured":"Webster L, Gudin J, Raffa RB, et al. Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion. Pain Medicine. 2020;21(4):714-723. https:\/\/doi.org\/10.1093\/pm\/pnz356","journal-title":"Pain Medicine."},{"key":"10221_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108710","volume":"223","author":"MS Schuler","year":"2021","unstructured":"Schuler MS, Dick AW, Stein BD. Growing racial\/ethnic disparities in buprenorphine distribution in the United States, 2007-2017. Drug and Alcohol Dependence. 2021;223:108710. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108710","journal-title":"Drug and Alcohol Dependence."},{"issue":"4","key":"10221_CR39","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3132","volume":"3","author":"TL Mark","year":"2020","unstructured":"Mark TL, Parish WJ, Zarkin GA. Association of Formulary Prior Authorization Policies With Buprenorphine-Naloxone Prescriptions and Hospital and Emergency Department Use Among Medicare Beneficiaries. JAMA Netw Open. 2020;3(4):e203132. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.3132","journal-title":"JAMA Netw Open."},{"issue":"12","key":"10221_CR40","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.29043","volume":"3","author":"MJ Nguemeni Tiako","year":"2020","unstructured":"Nguemeni Tiako MJ, Culhane J, South E, Srinivas SK, Meisel ZF. Prevalence and Geographic Distribution of Obstetrician-Gynecologists Who Treat Medicaid Enrollees and Are Trained to Prescribe Buprenorphine. JAMA Netw Open. 2020;3(12):e2029043. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.29043","journal-title":"JAMA Netw Open."},{"key":"10221_CR41","doi-asserted-by":"publisher","unstructured":"Andraka-Christou B, Capone MJ. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices. International Journal of Drug Policy. 2018;54:9\u201317. https:\/\/doi.org\/10.1016\/j.drugpo.2017.11.021","DOI":"10.1016\/j.drugpo.2017.11.021"},{"key":"10221_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2023.102494","volume":"36","author":"KR Hochstatter","year":"2023","unstructured":"Hochstatter KR, Nordeck C, Mitchell SG, Schwartz RP, Welsh C, Gryczynski J. Polysubstance use and post-discharge mortality risk among hospitalized patients with opioid use disorder. Preventive Medicine Reports. 2023;36:102494. https:\/\/doi.org\/10.1016\/j.pmedr.2023.102494","journal-title":"Preventive Medicine Reports."},{"key":"10221_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100128","volume":"5","author":"Y Pan","year":"2022","unstructured":"Pan Y, Feaster DJ, Odom G, et al. Specific polysubstance use patterns predict relapse among patients entering opioid use disorder treatment. Drug and Alcohol Dependence Reports. 2022;5:100128. https:\/\/doi.org\/10.1016\/j.dadr.2022.100128","journal-title":"Drug and Alcohol Dependence Reports."},{"issue":"4","key":"10221_CR44","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00127-021-02199-2","volume":"57","author":"J van Draanen","year":"2022","unstructured":"van Draanen J, Tsang C, Mitra S, et al. Mental disorder and opioid overdose: a systematic review. Soc Psychiatry Psychiatr Epidemiol. 2022;57(4):647-671. https:\/\/doi.org\/10.1007\/s00127-021-02199-2","journal-title":"Soc Psychiatry Psychiatr Epidemiol."},{"key":"10221_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108921","volume":"144","author":"R Smart","year":"2023","unstructured":"Smart R, Kim JY, Kennedy S, et al. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder. J Subst Abuse Treat. 2023;144:108921. https:\/\/doi.org\/10.1016\/j.jsat.2022.108921","journal-title":"J Subst Abuse Treat."},{"key":"10221_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108083","volume":"213","author":"DR Roehler","year":"2020","unstructured":"Roehler DR, Guy GP Jr, Jones CM. Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017-2018: A cross-sectional study. Drug Alcohol Depend. 2020;213:108083. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108083","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10221_CR47","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.1588","volume":"1","author":"B Saloner","year":"2018","unstructured":"Saloner B, Levin J, Chang HY, Jones C, Alexander GC. Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion. JAMA Netw Open. 2018;1(4):e181588. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.1588","journal-title":"JAMA Netw Open."},{"issue":"26","key":"10221_CR48","doi-asserted-by":"publisher","first-page":"697","DOI":"10.15585\/mmwr.mm6626a4","volume":"66","author":"GP Guy","year":"2017","unstructured":"Guy GP, Zhang K, Bohm MK, et al. Vital Signs: Changes in Opioid Prescribing in the United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017;66(26):697-704. https:\/\/doi.org\/10.15585\/mmwr.mm6626a4","journal-title":"MMWR Morb Mortal Wkly Rep."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10221-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10221-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10221-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:05:17Z","timestamp":1782403517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-026-10221-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10221"],"URL":"https:\/\/doi.org\/10.1007\/s11606-026-10221-z","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Research was determined not to involve human subjects by the Saint Louis University Institutional Review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"The authors declare that they do not have a conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}